Adverse events associated with sequential immune checkpoint inhibitor and alectinib in patients with ALK-rearranged advanced non-small-cell lung cancer
{{output}}
Background: ALK tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for ALK-rearranged [ALK fusion-positive (ALK+)] advanced non-small-cell lung cancer (NSCLC). In real-world practice, patients may receive immun... ...
